Real-world effectiveness of GLP-1RAs on Time in Range in pati ents with type 2 diabetes: A retrospective study

Abstract

Abstract Presently, there is a lack of real-world evidence on the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for improving Time in Range (TIR). To address this, we investigated the effect of GLP-1RAs on TIR among type 2 diabetes mellitus (T2DM) patients in real-world clinical practice. This multi-center, retrospective, real-world study included T2DM patients who previously used a Continuous Glucose Monitoring (CGM) system and received treatment with GLP-1RAs or oral antidiabetic drugs (OADs). According to propensity score matching, 238 patients were equally divided between the GLP-1RA and OAD groups. After 3–6 months of treatment, the TIR for the GLP-1RA and OAD groups was 75.2% and 67.2%, respectively (p < 0.001). The GLP-1RA group displayed a significantly lower Time above Range (TAR) and mean glucose than the OAD group (p < 0.001). Subgroup analysis revealed that, compared with that of liraglutide, administration of semaglutide and polyethylene glycol loxenatide (PEG-Loxe) significantly improved TIR over 3–6 months of treatment (p < 0.001). Taken together, these real-world findings indicate that GLP-1RAs are superior to OADs for improving TIR among T2DM patients and that a once-weekly GLP-1RA may be more effective than a once-daily GLP-1RA.